<DOC>
	<DOCNO>NCT02395055</DOCNO>
	<brief_summary>This clinical study phase 1 study carry establish pharmacokinetic equivalence equal safety tolerability profile BCD-057 ( adalimumab biosimilar candidate manufacture CJSC BIOCAD , Russia ) Humira use single subcutaneous injection healthy volunteer .</brief_summary>
	<brief_title>Comparative Clinical Trial Evaluate Pharmacokinetics , Tolerance Safety BCD-057 Humira Healthy Volunteers</brief_title>
	<detailed_description>This single center comparative double blind randomize clinical study pharmacokinetics , tolerance safety single subcutaneous injection BCD-057 ( CJSC BIOCAD , Russia ) Humira healthy volunteer . The purpose study demonstrate BCD-057 equivalent Humira term pharmacokinetics , tolerability safety single subcutaneous injection healthy volunteer . The study enroll 94 healthy volunteer , randomize 2 group ( 1:1 ratio ) : volunteer first group receive BCD-057 ; volunteer second group receive Humira . Both study reference drug use standard dose 40 mg .</detailed_description>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>subject provide informed consent ; male gender ; 18 45 year age inclusively ; body mass index ( BMI ) 18,5 30 kg/m2 ; absence clinically significant hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , immunologic , hematologic , dermatologic , neurologic abnormality screen or/and anamnesis ; parameter complete blood count , blood biochemistry urinalysis exceed reference value , use Study site laboratory . Evaluation require laboratory parameter must perform within 14 day randomization ; normal hemodynamic parameter : systolic BP 100 139 mm Hg , diastolic BP 60 90 mm Hg , heart rate 60 90 b/min ; ECG result normal age group ; absence chronic infection ( HIV , syphilis , hepatitis В С ) chronic inflammation ; absence active latent tuberculosis ; absence infection within 4 week randomization ; absence mental disorder condition , may affect ability participant follow Protocol ; health wellbeing ( volunteer 's opinion ) least 30 day randomization ; ability follow Protocol procedure ; consent volunteer sexual partner childbearing potential use adequate contraception screen period main study part ; absence alcohol drug addiction sign ( incl . history addiction ) ; consent consume alcohol within 24 hour SC injection BCD057/Humira use 10 unit alcohol per week study ( 1 alcohol unit equal ½ l beer ( 1 pint ) , 200 ml wine , 50 ml alcohol ) history adalimumab use TNF inhibitor ; know severe allergy ( anaphylaxis multidrug intolerance ) ; know intolerance monoclonal antibody excipients BCD057/Humira ; major surgery within 30 day ICF signing ; presence clinically significant hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , immunologic , hematologic , dermatologic , neurologic abnormality screen or/and anamnesis . infection require hospitalization , parenteral antiinfectives within 6 month randomization ; positive result test HIV1 HIV2 antibody , positive HbsAg , HBc IgM , total antibody HCV , positive result RPRtest ; 4 episode acute respiratory infection within 6 month randomization ; malignancy ( present history ) ; tuberculosis , include latent form ; shingle ( present history ) . history seizure ; disorder condition , may affect pharmacokinetics BCD057/Humira ( e.g . chronic liver disease , chronic kidney disease , cardiovascular disorder , lung disorder , endocrine disease , etc. ) . use systemic antimicrobial antifungal medicine within 2 month randomization ; regular oral parenteral use medicine , vitamin , biologically active additive within two week sign ICF ; use medicine , vitamin , biologically active additive within 30 day sign ICF ; use medicine , may influence immunity within 30 day sign ICF ; vaccination within 4 week prior randomization ; smoke 10 cigarette per day ; use alcohol , exceed 10 unit per week ( 1 alcohol unit equal ½ l beer ( 1 pint ) , 200 ml vine , 50 ml alcohol ) . History alcohol drug addiction ; donation 450 ml blood plasma within 2 month prior randomization ; simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation ; previous participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>